Metoject 25 mg Injektionsvätska, lösning i förfylld injektionspenna

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

Bipacksedel Bipacksedel (PIL)

11-12-2019

Produktens egenskaper Produktens egenskaper (SPC)

04-06-2020

Aktiva substanser:
metotrexat
Tillgänglig från:
medac Gesellschaft für klinische Spezialpräparate GmbH,
ATC-kod:
L04AX03
INN (International namn):
methotrexate
Dos:
25 mg
Läkemedelsform:
Injektionsvätska, lösning i förfylld injektionspenna
Sammansättning:
metotrexat 25 mg Aktiv substans
Receptbelagda typ:
Receptbelagt
Produktsammanfattning:
Förpacknings: Förfylld penna, 1 st (25 mg/0,5 ml); Förfylld penna, 24 st (25 mg/0,5 ml); Förfylld penna, 10 st (25 mg/0,5 ml); Förfylld penna, 6 st (25 mg/0,5 ml); Förfylld penna, 5 st (25 mg/0,5 ml); Förfylld penna, 4 st (25 mg/0,5 ml); Förfylld penna, 2 st (25 mg/0,5 ml); Förfylld penna, 15 st (25 mg/0,5 ml); Förfylld penna, 14 st (25 mg/0,5 ml); Förfylld penna, 12 st (25 mg/0,5 ml); Förfylld penna, 11 st (25 mg/0,5 ml)
Bemyndigande status:
Godkänd
Godkännandenummer:
55894
Tillstånd datum:
2018-01-30

Dokument på andra språk

Bipacksedel Bipacksedel - engelska

26-02-2021

Produktens egenskaper Produktens egenskaper - engelska

11-12-2019

Offentlig bedömningsrapport Offentlig bedömningsrapport - engelska

30-01-2018

Läs hela dokumentet

Package leaflet: Information for the user

Metoject 7.5 mg solution for injection in pre-filled pen

Metoject 10 mg solution for injection in pre-filled pen

Metoject 15 mg solution for injection in pre-filled pen

Metoject 20 mg solution for injection in pre-filled pen

Metoject 25 mg solution for injection in pre-filled pen

methotrexate

Read all of this leaflet carefully before you start using this medicine because it contains

important information for you.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you only. Do not pass it on to others. It may harm them,

even if their signs of illness are the same as yours.

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side

effects not listed in this leaflet. See section 4.

What is in this leaflet

What Metoject is and what it is used for

What you need to know before you use Metoject

How to use Metoject

Possible side effects

How to store Metoject

Contents of the pack and other information

1.

What Metoject is and what it is used for

Metoject is indicated for the treatment of

active rheumatoid arthritis in adult patients.

severe recalcitrant disabling psoriasis, which is not adequately responsive to other forms of

therapy such as phototherapy, PUVA, and retinoids, and severe psoriatic arthritis in adult

patients.

Rheumatoid arthritis

(RA)

is a chronic collagen disease, characterised by inflammation of the

synovial membranes (joint membranes). These membranes produce a fluid which acts as a lubricant

for many joints. The inflammation causes thickening of the membrane and swelling of the joint.

Psoriasis

is a common chronic skin disease, characterised by red patches covered by thick, dry,

silvery, adherent scales.

Psoriatic arthritis

is a kind of arthritis with psoriatic lesions of the skin and nails, especially at the

joints of fingers and toes.

Metoject modifies and slows down the progression of the disease.

2.

What you need to know before you use Metoject

Do not use Metoject if you

are allergic to methotrexate or any of the other ingredients of this medicine (listed in section 6).

suffer from liver or severe kidney diseases or blood diseases.

regularly drink large amounts of alcohol.

suffer from a severe infection, such as tuberculosis, HIV or other immunodeficiency syndromes.

suffer from mouth ulcers, stomach ulcer or intestinal ulcer.

are pregnant or breast-feeding (see section “Pregnancy, breast-feeding and fertility”).

receive vaccinations with live vaccines at the same time.

Warnings and precautions

Talk to your doctor or pharmacist before taking Metoject if you:

are elderly or if you feel generally unwell and weak.

have problems with the way your liver works.

suffer from dehydration (water loss).

Pregnant women should not administer Metoject or handle the prefilled pen.

Methotrexate should not come into contact with the surface of the skin or mucosa. In the event

of contamination, the affected area must be rinsed immediately with plenty of water.

Special precautionary measures for treatment with Metoject

Methotrexate temporarily affects sperm and egg production, which is reversible in most cases.

Methotrexate can cause miscarriage and severe birth defects. You must avoid becoming pregnant

when using methotrexate and for at least six months after treatment has stopped. See also section

“Pregnancy, breast-feeding and fertility”.

Recommended follow-up examinations and safety measures

Even when Metoject is administered in low doses, severe side effects can occur. In order to detect

them in time, check-ups and laboratory tests have to be carried out by your doctor.

Before therapy

Before starting the treatment, blood samples will be taken in order to check that you have enough

blood cells, tests to check your liver function, serum albumin (a protein in the blood) and kidney

function. Your doctor will also check if you suffer from tuberculosis (infectious disease in

combination with little nodules in the affected tissue) and a chest X-ray will be taken.

During therapy

You will have the following tests at least once a month during the first six months and at least every

three months thereafter:

Examination of the mouth and throat for changes of the mucosa

Blood tests

Check of liver function

Check of kidney function

Check of respiratory system and if necessary lung function test

Acute bleeding from the lungs in patients with underlying rheumatologic disease has been reported

with methotrexate. If you experience symptoms of spitting or coughing up blood you should contact

your doctor immediately.

Methotrexate may affect your immune system and vaccination results. It may also affect the result of

immunological tests. Inactive, chronic infections (such as herpes zoster [shingles], tuberculosis,

hepatitis B or C) may flare up.

During therapy with Metoject you must not be vaccinated with live

vaccines.

Radiation-induced dermatitis and sun-burn can reappear under methotrexate therapy (recall-reaction).

Psoriatic lesions can exacerbate during UV-irradiation and simultaneous administration of

methotrexate.

Enlarged lymph nodes (lymphoma) may occur and if this is the case therapy must be stopped.

Diarrhoea can be a possible side effect of Metoject and requires an interruption of therapy. If you

suffer from diarrhoea please speak to your doctor.

Certain brain disorders (encephalopathy / leukoencephalopathy) have been reported in cancer patients

receiving methotrexate. Such side effects cannot be excluded when methotrexate is used to treat other

diseases.

Other medicines and Metoject

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other

medicines. Please note that this also applies to medicines that you will take

in the future

The effect of the treatment may be affected if Metoject is administered at the same time as certain

other medicines:

Antibiotics

such as: tetracyclines, chloramphenicol, non-absorbable broad-spectrum antibiotics,

penicillines, glycopeptides, sulphonamides ciprofloxacin and cefalotin (medicines to

prevent/fight certain infections).

Non-steroidal anti-inflammatory

drugs or

salicylates

(medicines against pain and/or

inflammation such as acetylsalicylic acid, diclofenac and ibuprofen or pyrazole).

Probenecid

(medicine against gout).

Weak organic acids like loop diuretics (“water tablets”).

Medicines which may have adverse effects on the

bone marrow

, such as trimethoprim-

sulphamethoxazole (an antibiotic) and pyrimethamine.

Other

medicines

used to treat rheumatoid arthritis

such as leflunomide, sulphasalazine and

azathioprine.

Mercaptopurine (a

cytostatic

agent).

Retinoids (medicine against psoriasis and other dermatological diseases).

Theophylline (medicine against bronchial asthma and other lung diseases).

Some medicines against

stomach trouble

such as omeprazole and pantoprazole.

Hypoglycaemics (medicines that are used to

lower the blood sugar

Vitamins containing folic acid may impair the effect of your treatment and should only be taken when

advised by your doctor.

Vaccination with live vaccine must be avoided.

Metoject with food, drink and alcohol

Alcohol as well as large amounts of coffee, caffeine-containing soft drinks and black tea should be

avoided during treatment with Metoject

Pregnancy, breast-feeding and fertility

Pregnancy

Do not use Metoject during pregnancy

or if you are trying to become pregnant. Methotrexate can cause

birth defects, harm the unborn child or cause

miscarriage.

It is associated

with

malformations of the

skull, face, heart and blood vessels, brain and limbs. Therefore, it is very important that Methotrexate

is not given to pregnant patients or patients planning to become pregnant. In women of child-bearing

age, any possibility of pregnancy must be excluded with appropriate measures,e.g. pregnancy

testbefore starting treatment.

You must avoid becoming pregnant whilst taking methotrexate and for at least 6 months after

treatment is stopped by using reliable contraception throughout this time (see also section “Warnings

and precautions”).

If you do become pregnant during treatment or suspect you might be pregnant, speak to your doctor as

soon as possible. You should be offered advice regarding the risk of harmful effects on the child

through treatment.

If you wish to become pregnant you should consult your doctor, who may refer you for specialist

advice before the planned start of treatment.

Breast-feeding

Stop breast-feeding prior to and during treatment with Metoject.

Male fertility

The available evidence does not indicate an increased risk of malformations or miscarriage if the

father takes methotrexate less than 30 mg/week. However, a risk cannot be completely excluded.

Methotrexate may be genotoxic. This means that the medicine may cause genetic mutation.

Methotrexate can affect sperm production with the potential to cause birth defects. Therefore, you

should avoid fathering a child or to donate semen whilst taking methotrexate and for at least 6 months

after treatment is stopped.

Driving and using machines

Treatment with Metoject may cause adverse reactions affecting the central nervous system, such as

tiredness and dizziness. Thus the ability to drive a vehicle and/or to operate machines may, in certain

cases, be compromised. If you feel tired or drowsy do not drive or use machines.

Metoject contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per dose

; i.e. essentially “sodium-free”.

3.

How to use Metoject

Important warning about the dose of Metoject (methotrexate):

Use Metoject

only once a week

for the treatment of rheumatoid arthritis, and psoriasis and psoriatic

arthritis. Using too much of Metoject (methotrexate) may be fatal. Please read section 3 of this leaflet

very carefully. If you have any questions, please talk to your doctor or pharmacist before you take this

medicine.

Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if

you are not sure.

Your doctor decides on the dose, which is adjusted individually to you. Usually it takes 4 – 8 weeks

before there is any effect of the treatment.

Metoject is administered subcutaneously (under the skin) by or under the supervision of a physician or

healthcare staff as an injection

once a week only.

Together with your doctor you decide on a suitable

weekday each week on which you receive your injection.

Use in children and adolescents

Metoject is not recommended in children less than 3 years of age

due to insufficient experience in

this age group.

Method and duration of administration

Metoject is injected

once weekly!

The duration of the treatment is determined by the treating physician. Treatment of rheumatoid

arthritis, juvenile idiopathic arthritis, psoriasis vulgaris and psoriatic arthritis with Metoject is a long-

term treatment.

At the start of your treatment, Metoject may be injected by medical staff. However, your doctor may decide that

you can learn how to inject Metoject yourself. You will receive appropriate training for you to do this.

Under no

circumstances should you attempt to inject yourself, unless you have been trained to do so.

You can also find guidance on how to use Metoject in the section “Instructions for use” at the end of

this leaflet.

Please note that all of the contents have to be used.

The manner of handling and disposal of the medicine and pre filled pen must be in accordance with

local requirements

If you use more Metoject than you should

If you use more Metotrexate PEN medac than you should, talk to your doctor immediately.

If you forget to use Metoject

Do not take a double dose to make up for a forgotten dose.

If you stop using Metoject

If you stop using Metoject, talk to your doctor immediately.

If you have the impression that the effect of Metoject is too strong or too weak, talk to your doctor or

pharmacist.

4.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The frequency as well as the degree of severity of the side effects depends on the dosage level and the

frequency of administration. As severe side effects may occur even at low dosage, it is important that

you are monitored regularly by your doctor. Your doctor will do

tests to check for abnormalities

developing in the blood (such as low white blood cells, low platelets, lymphoma) and changes in the

kidneys and the liver.

Tell your doctor immediately

if you experience any of the following symptoms, as these may

indicate a serious, potentially life-threatening side effect, which require urgent specific treatment:

persistent dry, non-productive cough, shortness of breath and fever

; these may be signs of

an inflammation of the lungs [common]

spitting or coughing blood;

these might be signs of bleeding from the lungs [not known]

symptoms of liver damage such as yellowing of the skin and whites of the eyes

methotrexate can cause chronic liver damage (liver cirrhosis), formation of scar tissue in the

liver (liver fibrosis), fatty degeneration of the liver [all uncommon], inflammation of the liver

(acute hepatitis) [rare] and liver failure [very rare]

allergy symptoms such as skin rash including red itchy skin, swelling of the hands, feet,

ankles, face, lips, mouth or throat (which may cause difficulty in swallowing or

breathing) and feeling you are going to faint;

these may be signs of severe allergic reactions

or an anaphylactic shock [rare]

symptoms of kidney damage such as swelling of the hands, ankles or feet or changes in

frequency of urination or decrease (oliguria) or absence of urine (anuria);

these may be

signs of kidney failure [rare]

symptoms of infections, e.g. fever, chills, achiness, sore throat;

methotrexate can make you

more susceptible to infections. Severe infections like a certain type of pneumonia

Pneumocystis jirovecii pneumonia

) or blood poisoning (sepsis) may occur [rare]

symptoms such as weakness of one side of the body (stroke) or pain, swelling, redness

and unusual warmth in one of your legs (deep vein thrombosis); This may happen when

a dislodged blood clot causes a blockage of a blood vessel

(thromboembolic event) [rare]

fever and serious deterioration of your general condition, or sudden fever accompanied

by a sore throat or mouth, or urinary problems

; methotrexate can cause a sharp fall in

certain white blood cells (agranulocytosis) and severe bone marrow suppression [very rare]

unexpected bleeding, e.g. bleeding gums, blood in the urine, vomiting blood or bruising,

these can be signs of a severely reduced number of blood platelets caused by severe courses of

bone marrow depression [very rare]

symptoms such as severe headache often in combination with fever, neck stiffness,

feeling sick, vomiting, disorientation and sensitivity to light

may indicate an inflammation

of the membranes of the brain (acute aseptic meningitis) [very rare]

certain brain disorders (encephalopathy/ leukoencephalopathy) have been reported in cancer

patients receiving methotrexate. Such side effects cannot be excluded when methotrexate

therapy is used to treat other diseases. Signs of this kind of brain disorders may be

altered

mental state,

movement disorders (ataxia), visual disturbances or disturbances of

memory [not known]

severe skin rash or blistering of the skin (this can also affect your mouth, eyes and

genitals)

; these may be signs of conditions called Stevens Johnson syndrome or burned skin

syndrome (toxic epidermal necrolysis/Lyell’s syndrome) [very rare]

In the following, please find the other side effects that may occur:

Very common:

may affect more than 1 in 10 people

Inflammation of the mouth lining, indigestion, feeling sick, loss of appetite, abdominal pain.

Abnormal liver function test (ASAT, ALAT, bilirubin, alkaline phosphatase).

Common:

may affect up to 1 in 10 people

Mouth ulcers, diarrhoea.

Rash, reddening of the skin, itching.

Headache, tiredness, drowsiness.

Reduced blood cell formation with decrease in white and/or red blood cells and/or platelets

Uncommon

(may affect up to 1 in 100 people

Throat inflammation.

Inflammation of the bowels, vomiting, inflammation of pancreas, black or tarry stools,

gastrointestinal ulcers and bleeding.

Increased sensitivity to light, loss of hair, increased number of rheumatic nodules, skin ulcer,

shingles, inflammation of blood vessels, herpes-like skin rash, hives.

Onset of diabetes mellitus.

Dizziness, confusion, depression.

Decrease in serum albumin.

Decrease in the number of all blood cells and platelets.

Inflammation and ulcer of the urinary bladder or vagina, reduced kidney function, disturbed

urination.

Joint pain, muscle pain, reduction of bone mass.

Rare:

may affect up to 1 in 1,000 people

Inflammation of gum tissue.

Increased skin pigmentation, acne, blue spots on the skin due to vessel bleeding (ecchymosis,

petechiae), allergic inflammation of blood vessels.

Decreased number of anti-bodies in the blood.

Infection (incl. reactivation of inactive chronic infection), red eyes (conjunctivitis).

Mood swings (mood alterations).

Visual disturbances.

Inflammation of the sac around the heart, accumulation of fluid in the sac around the heart,

obstruction of cardiac filling due to fluid in the sac around the heart.

Low blood pressure.

Formation of scar tissue in the lung (pulmonary fibrosis), shortness of breath and bronchial

asthma, accumulation of fluid in the sac around the lung.

Stress fracture.

Electrolyte disturbances.

Fever, wound-healing impairment.

Very rare

(may affect up to 1 in 10,000 people):

Acute toxic dilatation of the gut (toxic megacolon).

Increased pigmentation of the nails, inflammation of the cuticles, (acute paronychia), deep

infection of hair follicles (furunculosis), visible enlargement of small blood vessels.

Pain, loss of strength or sensation of numbness or tingling / having less sensitivity to

stimulation than normal, changes in taste (metallic taste), convulsions, paralysis, meningism.

Impaired vision, non-inflammatory eye disorder (retinopathy).

Loss of sexual drive, impotence, male breast enlargement, defective sperm formation

(oligospermia), menstrual disorder, vaginal discharge.

Enlargement of lymphatic nodes (lymphoma).

Lymphoproliferative disorders (excessive growth of white blood cells).

Not known:

frequency cannot be estimated from the available data:

Increased number of white blood cells.

Nosebleed.

Proteins in urine.

Feeling of weakness.

Bone damage in the jaw (secondary to excessive growth of white blood cells).

Tissue destruction at injection site.

Redness and shedding of skin

Swelling

Subcutaneous application of methotrexate is locally well tolerated. Only mild local skin reactions

(such as burning sensations, erythema, swelling, discolouration, severe itching, pain) were observed,

decreasing during therapy.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects

not listed in this leaflet. You can also report side effects directly via (see details below). By reporting

side effects you can help provide more information on the safety of this medicine.

<To be completed nationally>

5.

How to store Metoject

Keep this medicine out of the sight and reach of children.

Store below 25 °C.

Keep the pre-filled pens in the outer carton in order to protect from light.

Do not use this medicine after the expiry date stated on the carton and pre-filled pen after EXP. The

expiry date refers to the last day of that month.

Do not use if this product has deteriorated or is damaged.

Do not dispose of any medicines via wastewater or household waste. Ask your pharmacist how to

dispose of medicines you no longer use. These measures will help protect the environment.

6.

Contents of the pack and other information

What Metoject contains

The active substance is methotrexate.

1 pre-filled pen with 0.15 ml solution contains 7.5 mg methotrexate.

1 pre-filled pen with 0.2 ml solution contains 10 mg methotrexate.

1 pre-filled pen with 0.3 ml solution contains 15 mg methotrexate.

1 pre-filled pen with 0.4 ml solution contains 20 mg methotrexate.

1 pre-filled pen with 0.5 ml solution contains 25 mg methotrexate.

The other ingredients are sodium chloride, sodium hydroxide and hydrochloric acid for pH

adjustment and water for injections.

What Metoject looks like and contents of the pack

This medicinal product is presented as a solution for injection in pre-filled pen.

The solution is clear, yellow-brown.

The following pack sizes are available:

Metoject is available in packs of 1, 2, 4, 5, 6, 10, 11, 12, 14, 15, and 24 pre-filled pens.

Not all pack sizes may be marketed.

The prefilled syringe within the pen may or may not have

graduations on the barrel. These graduations are non-functional.

Marketing Authorisation Holder and Manufacturer

medac Gesellschaft für klinische Spezialpräparate mbH

Theaterstr. 6

22880 Wedel

Phone:

+49 4103 8006-0

Fax:

+49 4103 8006-100

This medicinal product is authorised in the Member States of the EEA under the following

names:

Sweden

Metoject

Ireland

Metoject PEN

This leaflet was last revised 2021-02-26

Instructions for use

Recommendations

Carefully read the instructions below before starting your injection.

Always use the injection technique advised by your doctor, pharmacist or nurse.

Additional information

The manner of handling and disposal of the medicine and pre-filled pen must be in accordance with

local requirements. Pregnant women should not administer Metoject or handle the prefilled pen.

Methotrexate should not come into contact with the surface of the skin or mucosa. In the event of

contamination, the affected area must be rinsed immediately with plenty of water.

Metoject pre-filled pen components:

Injection button

Handling area

Transparent control zone

a) With cap before injection

b) After cap removal before injection

c) After injection

What you need to do before administering your injection

Wash your hands very carefully.

Remove the system from its packaging.

Check the Metoject pre-filled pen before using it:

If the Metoject pre-filled pen appears to be damaged,

do

not use

it. Use another one and contact your doctor,

pharmacist or nurse.

In case a small air bubble is visible through the transparent

control zone, this will not affect your dose nor will it harm

you.

If you are not able to see or to check the system correctly

prior to injection, ask someone around you for assistance.

Set the Metoject pre-filled pen on a clean flat surface (such as a table).

Where you should administer the injection

The most appropriate zones for your injection are:

- upper thighs,

- abdomen except around the navel.

If someone around you administers the injection for

you, the person may also use the top of the zone at the

back of the arm, just below the shoulder.

Change the injection area with each injection. This will

minimize any reactions at the injection site.

Never inject into areas where the skin is tender, bruised,

red or hard or where you have scars or stretch marks. If

you have psoriasis, you should not try to inject directly

into any raised, thick, red or scaly skin patches or

lesions.

How to prepare the injection

Choose an injection site and clean the area of and

around the chosen injection site. Clean your skin in

the chosen injection zone using soap and water.

Hold the Metoject pre-filled pen with one hand in the

handling area with the cap pointing upwards.

Do not remove the cap before you are ready to

administer the injection.

Use your other hand to gently pull the cap straight off

(do not bend or twist the cap). The cap has a small

needle shield that should come off with the cap

automatically. If the needle shield does not come off,

use another pen and contact your doctor, pharmacist

or nurse.

Do not press the button until you are ready to inject.

If you are unable to remove the cap, ask someone

around you for assistance.

Note: Once you have removed the cap, perform your injection without delay.

With your free hand, build a skin fold by gently

squeezing the area of the cleaned skin at the injection

site.

The fold must be held pinched until the Metoject pre-

filled pen is removed from the skin after the injection.

Position the uncapped transparent end of Metoject

pre-filled pen perpendicular to the fold of skin.

Without pressing the button

, push the Metoject pre-

filled pen firmly onto your skin in order to unlock the

button.

If you are unable to push the Metoject pre-filled pen to

the stop-point, ask someone around you for assistance.

How to administer the injection:

While holding the Metoject pre-filled pen firmly

against the skin,

now press

the button

with your

thumb.

You will hear a click which indicates the start of the

injection. Keep holding the pen against the raised skin

until all of the medicine is injected. This can take up

5

seconds

Note:

Do not remove the Metoject pre-filled pen from the skin before the end of the injection to avoid

incomplete injection.

If the injection is not triggered, release the button, make sure that the Metoject pre-filled pen is pressed

firmly against the skin and push hard on the button.

If you have difficulty with hearing, count 5 seconds from the moment you have pressed the button and

then lift the Metoject pre-filled pen from the injection site.

Remove the Metoject pre-filled pen from the injection

site, perpendicular to the skin (pull up).

The protective shield automatically moves into place

over the needle. The protective shield is then locked

and the needle is protected.

In case of a slight bleeding use a plaster.

Before disposing of the Metoject pre-filled pen, check

visually that there is no liquid left in the pen, at the bottom

of the

transparent control zone

. If there is liquid left in the

pen, not all of the medicine has been injected correctly and

you should consult your doctor.

Note

To avoid any injury,

never insert your fingers in the opening of the protective tube

covering the

needle.

Do not destroy the pen.

Whom should you contact in case of need

For any problem or question, contact your doctor, pharmacist or nurse.

If you or someone around you is injured by the needle, consult your doctor immediately and

dispose of the Metoject pre-filled pen.

Läs hela dokumentet

Marknadsförs ej för närvarande.

Produktinformation

Liknande Produkter

Sök varningar relaterade till denna produkt

Visa dokumenthistorik

Dela den här informationen